Table 4 Characteristics of COVID-19 patients who did not receive remdesivir.
Patients characteristics (N = 159) | N | (%) |
|---|---|---|
Age, years, median (range) | 71 (23–94) | |
Sex | ||
Male | 82 | 51.6 |
Female | 77 | 48.4 |
Race | ||
Japanese | 140 | 88.1 |
East-Asian | 4 | 2.5 |
South-Asian | 6 | 3.8 |
Lationo | 1 | 0.6 |
Caucasian | 7 | 4.4 |
Mix | 1 | 0.6 |
Severity of illness categories by NIH classification | ||
Asymptomatic | 4 | 2.5 |
Mild | 22 | 13.8 |
Moderate | 60 | 37.7 |
Severe | 48 | 30.2 |
Critical | 25 | 15.7 |
Steroid dose | ||
Steroid pulse | 18 | 11.3 |
Non-pulse | 56 | 35.2 |
No | 85 | 53.5 |
Comorbidities | ||
Diabetes mellitus | 44 | 28.0 |
Hypertension | 47 | 29.9 |
Hyperlipidemia | 28 | 17.8 |
D-dimer, µg/mL | ||
Normal | 34 | 21.7 |
Elevated (> 1.0 μg/mL) | 112 | 71.3 |
Unexamined | 13 | 8.3 |
Increase in pancreatic enzyme levels | ||
Grade 3 | 3 | 1.9 |
Grade 4 | 0 | 0 |
Outcome | ||
Discharged | 143 | 89.9 |
Death | 15 | 9.4 |
Hospitalized | 1 | 0.6 |
